{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000088","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-09-01T20:13:12+00:00","discovered_at":"2026-09-01T20:14:00.232887+00:00","generated_at":"2026-09-01T20:14:05.688095+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Emergent BioSolutions gets $24M BARDA contract modification for CYFENDUS anthrax vaccine","bullets":["Contract modification valued at ~$24M from BARDA to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness.","Modification No. 21 to BARDA AV7909 Contract, effective Aug 18, 2026; announced Sept 1, 2026.","Earlier in 2026, Emergent announced up to $21.5M delivery order for BioThrax to U.S. Department of War.","CYFENDUS approved by FDA in July 2023 as two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000088","json":"https://secwatch.observer/filing/0001367644-26-000088.json","markdown":"https://secwatch.observer/filing/0001367644-26-000088.md","text":"https://secwatch.observer/filing/0001367644-26-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/0001367644-26-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/ebs-20260818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T20:14:05.688095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}